36 results about "Myocardial ischemia/hypoxia" patented technology

The invention belongs to the technical field of medicaments or foods and discloses a medicinal composition. The medicinal composition comprises the following raw materials in part by weight: 10 to 1,000 parts of rhodioloside and 1 to 200 parts of D-ribose. The medicinal composition of the invention has a therapeutical effect on myocardial ischemia and anoxia, also can improve cardiovascular functions, controls the accumulation of blood platelets and the formation of thrombus, and has a certain effect of reducing blood lipid. The medicinal composition of the invention has the effects of tonifying qi, invigorating blood circulation, promoting coronary circulation and relieving pain, is used for chest obstruction which is caused by qi deficiency and blood stasis and is manifested as chest stuffiness, stabbing pain or dull pain, palpitation, short breath, fatigue, acratia, lack of qi and no desire to speak, light-headedness and the like, and is used for coronary heart disease and angina pectoris with above expressions.

The invention discloses a heart intervention catheter butt joint bracket which comprises a main body plate, wherein the upper surface of the main body plate close to the front side is provided with a straight-shaped butt joint groove which penetrates through two ends of the main body plate is arranged on the main body plate and close to the front side of the main body plate; a front inclined plate inclining upwards is arranged on the butt joint groove and the main body plate in the front; and the middle part of the butt joint groove is provided with a butt joint mark. The heart intervention catheter butt joint bracket provided by the invention has the advantages that in use, a catheter and a guide wire interface are bidirectionally placed in a groove on the bracket, the mutual butt joint operation is carried out by utilizing the guide effect of the groove, and the operation is successful at one time; the device is simple in manufacturing, materials are easy to get, the volume is small, the manufacturing cost is low, the operation conditions are not restricted, and the catheter sacculus and the bracket can not be damaged; the operation time is saved, thus myocardial ischemia and oxygen deficiency for patients is reduced, and the heat functions are improved; and meanwhile, the energy and physical agility of surgeons are saved as much as possible, the essential conditions for the successful surgery are provided, and the working efficiency is improved.

The invention relates to an anti-myocardial ischemia-hypoxia polypeptide, composition, application thereof and polypeptide medicine. Wherein, the sequence of the anti-myocardial ischemia-hypoxic polypeptide has: the amino acid sequence shown in SEQ ID NO.1, or has at least 70% homology with the amino acid sequence shown in SEQ ID NO.1 amino acid sequence. The above-mentioned anti-myocardial ischemia-hypoxia polypeptide can significantly reduce the activity level and release of lactate dehydrogenase in cells, and can protect cells; at the same time, the anti-myocardial ischemia-hypoxia polypeptide can significantly improve cell survival under hypoxia Rate. Animal experiments show that the polypeptide can significantly reduce lactate dehydrogenase (LDH) and creatine kinase (CK) in rat serum, and has a significant protective effect on myocardial cell ischemic injury, preventing and / or treating coronary atherosclerosis Sclerotic heart disease, reduce the mortality rate of myocardial infarction.

The invention discloses a Crotane-type diterpene compound 1-6 represented by a structural formula, a pharmaceutical composition using it as an active ingredient, a preparation method thereof, and an application thereof in preparing a cardioprotective drug. Pharmacological activity test shows: compound 1-6 of the present invention can significantly increase cardiomyocyte survival rate, finds compound 1-6 simultaneously to H 2 o 2 Inducing primary cardiomyocyte injury in suckling rats has a better protective effect in a concentration-dependent manner. The results of this study indicate that the compounds can be developed into cardiomyocyte-protecting drugs for the prevention and treatment of cardiovascular diseases such as coronary heart disease, angina pectoris, myocardial infarction, myocarditis, and arrhythmia caused by myocardial ischemia and hypoxia.

The invention discloses an application of Lei Gonglian extract in preparing anti-myocardial ischemia and hypoxia products. The present invention has carried out in-depth research on the activity of the extract of Lei Gonglian, through the impact on the T wave of the electrocardiogram of acute myocardial ischemia in mice induced by ISO, the impact on the ability of mice to withstand hypoxia under normal pressure, and the effect on acute myocardial ischemia in mice induced by ISO. The influence test of blood normal pressure hypoxia tolerance and the impact test on mouse decapitation ischemia hypoxia wheezing time, it can be seen that the extract of Lei Gonglian can effectively inhibit the elevation of myocardial ST-T, and improve the normal pressure hypoxia tolerance of normal mice. Oxygen capacity, improve the ability of mice to withstand acute myocardial ischemia and normal pressure hypoxia caused by ISO, and prolong the time of decapitated mice ischemic and hypoxic wheezing, indicating that the extract of Lei Gonglian has a significant effect on myocardial ischemia and hypoxia. Therefore, the extract of Lei Gonglian has obvious activity, stable performance, safety and reliability, and can be used to prepare anti-myocardial ischemia and hypoxia products. In addition, the raw material is easy to obtain, the extraction process is simple, and the industrial production is easy.

The invention discloses an application of 5,6,7,8- trihydroxy-8-methoxyflavone in preparing an anti-hypoxic drug which is the drug for preventing and treating hypoxic injury diseases; the hypoxic injury diseases are high-altitude low-pressure oxygen deficit-caused acute high altitude diseases, cerebral ischemia hypoxic diseases or myocardial ischemia hypoxic diseases. The application has beneficial effects as follows: an experiment proves that the 5,6,7,8- trihydroxy-8-methoxyflavone has a remarkable anti-hypoxic effect, and an effect tending to be better than that of acetazolamide; the anti-hypoxic drug prepared by applying the 5,6,7,8- trihydroxy-8-methoxyflavone as an active ingredient can be used for preventing and treating hypoxic injuries or treating various hypoxic pathological states caused by oxygen content drop in external environment, also can be used for preventing or treating hypoxic pathological states of heart, brain, respiratory system, and the like as external normal oxygen cannot sufficiently get to a body due to diseases, and the like, and further can be used for preventing or treating the pathological state that relative oxygen supply is insufficient as oxygen consumption needed for activities of the body exceeds physiological mobilization ability.

The invention relates to a medicinal composition for improving blood circulation and relieving stasis, wherein the composition is prepared from the following raw materials (by weight portion): panax notoginseng saponins 10-200 parts, red sage root 125-2500 parts, the invention also relates to the process for preparing the composition and use thereof.

The invention relates to an anti-myocardial ischemia-hypoxia polypeptide, composition, application thereof and polypeptide medicine. Wherein, the sequence of the anti-myocardial ischemia-hypoxic polypeptide has: the amino acid sequence shown in SEQ ID NO.1, or has at least 70% homology with the amino acid sequence shown in SEQ ID NO.1 amino acid sequence. The above-mentioned anti-myocardial ischemia-hypoxia polypeptide can significantly reduce the activity level and release of lactate dehydrogenase in cells, and can protect cells; at the same time, the anti-myocardial ischemia-hypoxia polypeptide can significantly improve cell survival under hypoxia Rate. Animal experiments show that the polypeptide can significantly reduce lactate dehydrogenase (LDH) and creatine kinase (CK) in rat serum, and has a significant protective effect on myocardial cell ischemic injury, preventing and / or treating coronary atherosclerosis Sclerotic heart disease, reduce the mortality rate of myocardial infarction.